Vif inhibitors (Rigel)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameVif inhibitors (Rigel)
Drug Alias Nameubiquitin ligase program (Rigel)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAPOBEC3 deaminase modulatorsUbiquitin-protein ligases modulators
TargetsUbiquitin-protein ligasesAPOBEC3 deaminase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A